TrialJournal of clinical oncology : official journal of the American Society of Clinical Oncology2014

Combined BRAF (Dabrafenib) and MEK inhibition (Trametinib) in patients with BRAFV600-mutant melanoma experiencing progression with single-agent BRAF inhibitor.

Douglas B Johnson et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.